VC-backed Spero Therapeutics sets IPO pricing terms

Cambridge, Massachusetts-based Spero Therapeutics, a biopharmaceutical company focused on developing treatments for bacterial infections, has priced its IPO of five million shares at a price between $14 and $16 per share. Spero is planning on trading the stock on the NASDAQ under the ticker symbol "SPRO." BofA Merrill Lynch, Cowen and Company LLC and Stifel are the lead underwriters. Spero's backers include GV, RA Capital Management, Rock Springs Capital, Atlas Venture, MRL Ventures Fund, Lundbeckfonden Ventures, The Kraft Group and Osage University Partners.

North AmericaUSBriefs